西非艾滋病毒队列中向基于多替拉韦的抗逆转录病毒疗法过渡过程中的性别差异
Sex-Based Disparities in the Transition to Dolutegravir-Based Antiretroviral Therapy in West African HIV Cohorts.
作者信息
Tiendrebeogo Thierry, Malateste Karen, Poda Armel, Minga Albert, Messou Eugene, Chenal Henri, Ezechi Oliver, Ekouevi Didier K, Ofotokun Igho, Jaquet Antoine
机构信息
National Institute for Health and Medical Research UMR 1219, Research Institute for Sustainable Development EMR 271, Bordeaux Population Health Research Centre, University of Bordeaux, Bordeaux, France.
Department of Infectious Diseases, Université Nazi Boni, Bobo-Dioulasso, Burkina Faso.
出版信息
Open Forum Infect Dis. 2024 Mar 19;11(5):ofae139. doi: 10.1093/ofid/ofae139. eCollection 2024 May.
Transition to dolutegravir among 21 167 individuals experienced in antiretroviral therapy in West Africa showed heterogeneous timelines and patterns. Initially reported sex disparities tended to catch up over time with persisting disparities, according to contributing HIV clinics. Key factors facilitating dolutegravir switch were male sex, age <50 years, viral suppression, and regimens not based on protease inhibitors.
在西非21167名有抗逆转录病毒治疗经验的个体中向多替拉韦的转换显示出不同的时间线和模式。根据提供数据的艾滋病诊所的数据，最初报告的性别差异随着时间的推移往往会逐渐缩小，但仍存在差距。促进转换为多替拉韦的关键因素包括男性、年龄小于50岁、病毒抑制以及非基于蛋白酶抑制剂的治疗方案。
Zotero 插件